Two globally oriented drugmakers, Pfizer and Sanofi, are making moves that some may interpret as attempts to allay the pharma industry‘s reputation for being “only in it for the money” but could potentially benefit poorer countries if all goes to plan.
Sanofi and GSK are touting their latecomer protein-based Covid-19 vaccine as a potential game changer in the fight against the Omicron variant.
Sanofi has joined forces with McLaren Racing in a move it hopes will accelerate its manufacturing efficiency and performance drive. As the French drugmaker’s CEO Paul Hudson put it, “we want to run our lines with the speed, precision and efficiency of a Formula One racing team.”
Sanofi has announced it will list its Active Pharmaceutical ingredients company EuroAPI on the Euronext stock exchange in Paris on May 6. Each of the French drugmaker’s shareholders will receive one share in EuroAPI for 23 Sanofi shares in addition to a cash dividend of €3.33 per Sanofi share.
French drugmaker Sanofi has signed an exclusive worldwide collaboration agreement with IGM Biosciences, a clinical-stage biotechnology company. The deal focuses on creating and developing and commercializing engineered IgM antibody antagonists against three oncology targets, along with three immunology/inflammation targets.
Sanofi has agreed a €300 million collaboration with private equity investor Blackstone Life Sciences (BXLS) to advance its innovative treatment for multiple myeloma (MM) Sarclisa (isatuximab). The French drugmaker said it will continue to fully manage the clinical program and retain full rights and control of the treatment.
After several delays, Sanofi and GlaxoSmithKline are preparing to submit data to regulatory authorities to support approval of their adjuvanted protein vaccine against Covid-19.
In the VAT 0002 extension trial investigating the safety and immunogenicity of the protein-based recombinant adjuvanted Covid-19 vaccine they are partly developing as a booster, Sanofi and GlaxoSmithKline said the shot delivered a “consistently strong immune response” and was well tolerated, regardless of the vaccine it followed.
French drugmaker Sanofi is taking an equity stake worth $180 million in and entering a new strategic collaboration with artificial intelligence (AI) and precision medicine specialist Owkin.
French pharma Sanofi is investing $60 million in Gyroscope Therapeutics, a UK-based clinical-stage gene therapy company focused on eye diseases. Sanofi will initially invest $40 million, with the remaining funds contingent on a future qualifying investment round and the satisfaction of certain closing conditions.
A year ago unthinkable, the market for mRNA-based Covid-19 vaccines appears to be headed for saturation, even though, or perhaps because, there now seem to be more products on the market than first-world consumers want or need.
Sanofi has completed the $3.2 billion acquisition of US biotech Translate Bio after the tender offer for all shares expired as scheduled at midnight US Eastern Daylight Time on Sept. 4. The minimum tender condition and all of the other conditions to the offer were satisfied, the French drugmaker said.
Sanofi is continuing its drive to diversify and upgrade its pharmaceuticals portfolio through acquisitions. In its latest move, the French drugmaker said it has signed a definitive merger agreement with US biotech Kadmon, a biopharmaceutical company specializing in treatments for unmet needs in transplant medication.
French drugmaker Sanofi may reconsider plans to acquire Translate Bio at the conditions recently announced, the US biotech said in a filing with the US Securities and Exchange Commission (SEC). Translate said Sanofi withdrew and refiled the proposed buyout information recently provided to allow the FTC more time to study it.
French drugmaker Sanofi has signed a definitive agreement to acquire Translate Bio, the clinical-stage mRNA therapeutics company with which it is currently cooperating on a Covid-19 vaccine. Both boards have unanimously approved the proposed all-cash transaction.
The human medicines committee of the European Medicines Agency, CHMP, has begun a rolling review of the Covid-19 vaccine developed by Sanofi Pasteur, which following approval is planned to be marketed by drugmaker Sanofi and UK pharma Glaxo SmithKline.
French drugmaker Sanofi plans to invest around €400 million annually in a center of excellence for mRNA vaccines that it hopes will accelerate the development and delivery of the next-generation vaccine portfolio it has built up in collaboration with US biotech Translate Bio. The company said the project will be “fully financed” through resource reallocation.
As part of its drive to reduce the complexity of its Consumer Healthcare (CHC) portfolio, French drugmaker Sanofi has agreed to sell 16 products marketed exclusively in Europe to German generics manufacturer Stada.
After seeing encouraging results with their adjuvanted recombinant Covid-19 vaccine candidate across all adult age groups in a recently completed Phase 2 trial, Sanofi and GlaxoSmithKline (GSK) are preparing to launch a global Phase 3 randomized double-blind study “in the coming weeks.”
The European Commission has confirmed rumors that it has initiated legal action against AstraZeneca for failing to meet contractual obligations for deliveries of Its Covid-19 vaccine. Health commissioner Stella Kyriakides said the action is being taken jointly with all 27 member states.
In partnership with the Singapore Economic Development Board (EDB), French drugmaker Sanofi is planning to invest more than €400 million to create what it said is a “unique vaccine production center that pushes the boundaries of operations through cutting edge manufacturing and digital technologies.” The new site will mainly supply the Asian region and complement existing manufacturing capability in Europe and North America.
French multinational pharma Sanofi will invest more than €600 million in a new vaccine manufacturing plant at its existing site in Toronto, Canada.
The European Chemical Industry has set out on an ambitious path to become carbon neutral. Germany, as one of the major chemical manufacturing nations, has committed to achieve this goal by 2050.
As one glitch after another at Covid vaccine suppliers upends deliveries, the German federal government is drawing up plans to build up production within its borders, federal health minister Jens Spahn said at a weekly news conference, thereby confirming remarks made by future vaccine commissioner Christoph Krupp in a pre-published newspaper interview.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
Germany’s Sirion Biotech has signed a license and collaboration agreement with major French pharma Sanofi on viral vector-based gene therapy. Financial terms of the agreement were not disclosed. The partners aim to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs.
On the same day that Sanofi and GSK announced the start of a new Phase 2 study of their delayed adjuvanted recombinant protein-based Covid-19 vaccine candidate, Sanofi disclosed it had signed an agreement to manufacture 12 million doses of Johnson & Johnson’s single-dose adenovirus-based Covid vaccine.
French pharma Sanofi is once again boosting its immunotherapy capabilities, this time with the acquisition of UK biotech Kymab. The company will make an upfront payment of about $1.1 billion plus up to $350 million upon Kymab achieving certain milestones.
The International Society for Pharmaceutical Engineering (ISPE) has announced Sanofi as the 2020 Facility of the Year Awards (FOYA) Overall Winner.
French pharma Sanofi is boosting once again its immunology portfolio with an agreement to buy Dutch biotech Kiadis for €308 million.
French drugmaker Sanofi has completed its acquisition of US-based Principia Biopharma for $100 per share in cash. The takeover worth altogether $3.7 billion was sealed following expiration of the tender offer for all of Principia’s shares on Sept. 25.
Both the Sanofi/GlaxoSmithKline partnership and US vaccine producer Moderna this week announced new advance purchase agreements with Canada for their Covid-19 vaccine candidates.
Sanofi and GSK have agreed a deal with the EU to supply up to 300 million doses of their recombinant protein-based Covd-19 vaccine pending regulatory approval, which is expected sometime in the first half of 2021.
With some potential Covid-19 vaccine makers suggesting they could have a candidate ready for approval and maybe even deployment this autumn, concerns are arising that a doubting public could shun inoculation.
After months of uncertainty and anxious glances across the water as potential Covid-19 vaccine manufacturers made deal after deal with other political blocs, the EU over the past four weeks has made rapid strides toward securing supplies for its 27 member states.
